BridgeMD
New treatment option for Depression
Official title Changing Tactics? Optimizing ECT in Difficult-to-treat Depression
ClinicalTrials.gov ID: NCT05923801
What this study is testing
- What it's testing
- The goal of this randomized controlled trial is to address which treatment strategy (continue right unilateral (RUL) ECT or switch to bitemporal (BT) ECT speeds up recovery and has the least impact on memory function, in case of early non-response during an acute course of ECT for difficult-to-treat depression. The main questions it aims to answer are: Assess the antidepressant efficacy and cognitive impact of the continuation of an ongoing treatment with RUL ECT compared to switching the treatment technique to BT ECT, in patients failing to show an early response to an acute course of ECT for major depression; Assess group and subject-specific trajectories of depressive symptom severity and neurocognitive performance during the acute ECT course and up to 3 months post-treatment.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
- Age 18 or older
- Diagnosis of major depressive disorder (DSM-5 296.21-30) or bipolar disorder, depressed (DSM-5 296.51-54; 296.84).
You likely can't join if
- Contra-indication for general anesthesia
- Non-Dutch speaking
- Diagnosis of schizoaffective disorder or schizophrenia
- Diagnosis of substance use disorder in the past six months
- Diagnosis of neurocognitive disorder or intellectual disability alongside a MoCA score \<23
- Previous ECT course in the past three months
See the full eligibility criteria
- Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
- Age 18 or older
- Diagnosis of major depressive disorder (DSM-5 296.21-30) or bipolar disorder, depressed (DSM-5 296.51-54; 296.84).
- Contra-indication for general anesthesia
- Non-Dutch speaking
- Diagnosis of schizoaffective disorder or schizophrenia
- Diagnosis of substance use disorder in the past six months
- Diagnosis of neurocognitive disorder or intellectual disability alongside a MoCA score \<23
- Previous ECT course in the past three months
- Participation in an treatment Trial with an investigational medicinal product or device
- Pregnancy
The study team makes the final eligibility decision.
Where it's taking place
- Kortenberg, Belgium
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Kortenberg, Belgium. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.